Abivax S.A. American Depositary Receipt (2X10)
XSTU 
NASDAQ (NMS) Primary XSTU Summary
2X10 Chart
Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results. Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
French biotech Abivax's shares climb on Eli Lilly bid rumors
French biotech company Abivax's shares jumped by 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly might be interested in bidding for the business.
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abivax S.A. American Depositary Receipt (2X10) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Abivax S.A. American Depositary Receipt ever had a stock split?
Abivax S.A. American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Marc M. P. de Garidel CEO | XSTU Exchange | US00370M1036 ISIN |
| FR Country | 69 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ABIVAX Société Anonyme operates in the forefront of biotechnology with a focus on discovering and developing therapeutic solutions aimed at modulating the body's natural immune response. Founded in 2013 and with its headquarters in Paris, France, this clinical-stage company is dedicated to addressing chronic inflammatory diseases through innovative treatments. By leveraging the body's own regulatory mechanisms, ABIVAX aims to provide effective and potentially pioneering therapies for diseases that currently have limited treatment options.
Products and Services
- Obefazimod:
As the lead drug candidate of ABIVAX, obefazimod represents a significant advancement in the treatment of chronic inflammatory diseases. Currently, it is undergoing Phase 3 clinical trials for its efficacy against moderately to severely active ulcerative colitis in adults. This therapeutic approach underscores ABIVAX’s commitment to tackling unmet medical needs within the realm of inflammatory diseases through the utilization of the body's inherent mechanisms for restoring immune balance.
Contact Information
